(VIANEWS) – Genmab (GMAB), ESCO Technologies (ESE), Chubb Corporation (CB) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Genmab (GMAB)
40.6% sales growth and 14.87% return on equity
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company also develops Teclistamab, which is in Phase 2 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
Earnings Per Share
As for profitability, Genmab has a trailing twelve months EPS of $0.96.
PE Ratio
Genmab has a trailing twelve months price to earnings ratio of 32.77. Meaning, the purchaser of the share is investing $32.77 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.87%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 16.1%, now sitting on 17.02B for the twelve trailing months.
Sales Growth
Genmab’s sales growth is negative 4% for the present quarter and 40.6% for the next.
Yearly Top and Bottom Value
Genmab’s stock is valued at $31.46 at 14:22 EST, way under its 52-week high of $47.50 and way higher than its 52-week low of $27.74.
Volume
Today’s last reported volume for Genmab is 267696 which is 67.02% below its average volume of 811731.
Previous days news about Genmab(GMAB)
- According to Zacks on Tuesday, 28 November, "AbbVie (ABBV Quick QuoteABBV – Free Report) along with partner Genmab (GMAB Quick QuoteGMAB – Free Report) announcedthat the FDA has granted breakthrough therapy designation ("BTD") to epcoritamab for treating adults with relapsed or refractory ("R/R") follicular lymphoma ("FL"), after two or more lines of therapies.", "Alongside the above news, AbbVie and Genmab also announced that the European Medicines Agency ("EMA") has validated a regulatory filing for epcoritamab in the same indication. "
2. ESCO Technologies (ESE)
18.6% sales growth and 8.57% return on equity
ESCO Technologies Inc. produces and supplies engineered products and systems for industrial and commercial markets worldwide. It operates through Aerospace & Defense, Utility Solutions Group, and RF Shielding and Test segments. The Aerospace & Defense segment designs and manufactures filtration products, including hydraulic filter elements and fluid control devices used in commercial aerospace applications; filter mechanisms used in micro-propulsion devices for satellites; and custom designed filters for manned aircraft and submarines. It also designs, develops, and manufactures elastomeric-based signature reduction solutions for U.S. naval vessels; and mission-critical bushings, pins, sleeves, and precision-tolerance machined components for landing gear, rotor heads, engine mounts, flight controls, and actuation systems for the aerospace and defense industries. The Utility Solutions Group segment provides diagnostic testing solutions that enable electric power grid operators to assess the integrity of high-voltage power delivery equipment; and decision support tools for the renewable energy industry, primarily wind and solar. The RF Shielding and Test segment designs and manufactures RF test and secure communication facilities, acoustic test enclosures, RF and magnetically shielded rooms, RF measurement systems, and broadcast and recording studios; and RF absorptive materials and filters, active compensation systems, antennas, antenna masts, turntables, electric and magnetic probes, RF test cells, proprietary measurement software, and other test accessories to perform various tests. It also provides services, such as calibration for antennas and field probes, chamber certification, field surveys, customer training, and various product tests. The company distributes its products through a network of distributors, sales representatives, direct sales teams, and in-house sales personnel. The company was incorporated in 1990 and is based in St. Louis, Missouri.
Earnings Per Share
As for profitability, ESCO Technologies has a trailing twelve months EPS of $3.53.
PE Ratio
ESCO Technologies has a trailing twelve months price to earnings ratio of 29.74. Meaning, the purchaser of the share is investing $29.74 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.57%.
Yearly Top and Bottom Value
ESCO Technologies’s stock is valued at $104.98 at 14:22 EST, under its 52-week high of $109.57 and way above its 52-week low of $85.01.
Earnings Before Interest, Taxes, Depreciation, and Amortization
ESCO Technologies’s EBITDA is 55.51.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 0.8% and 21.7%, respectively.
Revenue Growth
Year-on-year quarterly revenue growth grew by 8.8%, now sitting on 939.88M for the twelve trailing months.
3. Chubb Corporation (CB)
10.1% sales growth and 13.51% return on equity
Chubb Limited provides insurance and reinsurance products worldwide. The company's North America Commercial P&C Insurance segment offers commercial property, casualty, workers' compensation, package policies, risk management, financial lines, marine, construction, environmental, medical, cyber risk, surety, and excess casualty; and group accident and health insurance to large, middle market, and small commercial businesses. Its North America Personal P&C Insurance segment provides affluent and high net worth individuals and families with homeowners, automobile and collector cars, valuable articles, personal and excess liability, travel insurance, and recreational marine insurance and services. The company's North America Agricultural Insurance segment offers multiple peril crop and crop-hail insurance; and coverage for farm and ranch property, and commercial agriculture products. Its Overseas General Insurance segment provides coverage for traditional commercial property and casualty; specialty categories, such as financial lines, marine, energy, aviation, political risk, and construction risk; and group accident and health, and traditional and specialty personal lines for corporations, middle markets, and small customers through retail brokers, agents, and other channels. The company's Global Reinsurance segment offers traditional and specialty reinsurance under the Chubb Tempest Re brand to property and casualty companies. Its Life Insurance segment provides protection and savings products comprising whole life, endowment plans, individual term life, group term life, medical and health, personal accident, credit life, universal life, and unit linked contracts. It markets its products primarily through insurance and reinsurance brokers. The company was formerly known as ACE Limited and changed its name to Chubb Limited in January 2016. Chubb Limited was incorporated in 1985 and is headquartered in Zurich, Switzerland.
Earnings Per Share
As for profitability, Chubb Corporation has a trailing twelve months EPS of $17.08.
PE Ratio
Chubb Corporation has a trailing twelve months price to earnings ratio of 13.35. Meaning, the purchaser of the share is investing $13.35 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.51%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 15.3%, now sitting on 48.26B for the twelve trailing months.
4. Regeneron Pharmaceuticals (REGN)
7.4% sales growth and 17.22% return on equity
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Earnings Per Share
As for profitability, Regeneron Pharmaceuticals has a trailing twelve months EPS of $35.09.
PE Ratio
Regeneron Pharmaceuticals has a trailing twelve months price to earnings ratio of 23.36. Meaning, the purchaser of the share is investing $23.36 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.22%.
Yearly Top and Bottom Value
Regeneron Pharmaceuticals’s stock is valued at $819.61 at 14:22 EST, under its 52-week high of $853.97 and way above its 52-week low of $668.00.
Volume
Today’s last reported volume for Regeneron Pharmaceuticals is 167279 which is 61.56% below its average volume of 435241.
5. Gartner (IT)
6.3% sales growth and 416.64% return on equity
Gartner, Inc. operates as a research and advisory company in the United States, Canada, Europe, the Middle East, Africa, and internationally. It operates through three segments: Research, Conferences, and Consulting. The Research segment delivers its research primarily through a subscription service that include on-demand access to published research content, data and benchmarks, and direct access to a network of research experts. The Conferences segment offers business professionals in an organization the opportunity to learn, share, and network. The Consulting segment offers market research, custom analysis, and on-the-ground support services. This segment also offers actionable solutions for IT-related priorities, including IT cost optimization, digital transformation, and IT sourcing optimization. Gartner, Inc. was founded in 1979 and is headquartered in Stamford, Connecticut.
Earnings Per Share
As for profitability, Gartner has a trailing twelve months EPS of $11.61.
PE Ratio
Gartner has a trailing twelve months price to earnings ratio of 36.97. Meaning, the purchaser of the share is investing $36.97 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 416.64%.
Volume
Today’s last reported volume for Gartner is 101411 which is 79.46% below its average volume of 493782.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is a negative 24.1% and a negative 8%, respectively.
Sales Growth
Gartner’s sales growth is 5.4% for the present quarter and 6.3% for the next.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Gartner’s EBITDA is 89.11.
Previous days news about Gartner(IT)
- The zacks analyst blog highlights gartner, the progressive, intercontinental hotels, cboe global markets and novo nordisk. According to Zacks on Tuesday, 28 November, "Stocks recently featured in the blog include: Gartner Inc. (IT Quick QuoteIT – Free Report) , The Progressive Corp. (PGR Quick QuotePGR – Free Report) , InterContinental Hotels Group plc (IHG Quick QuoteIHG – Free Report) , Cboe Global Markets Inc. (CBOE Quick QuoteCBOE – Free Report) and Novo Nordisk A/S (NVO Quick QuoteNVO – Free Report) ."
6. National Retail Properties (NNN)
6% sales growth and 9.46% return on equity
NNN REIT invests primarily in high-quality retail properties subject generally to long-term, net leases. As of March 31, 2023, the company owned 3,449 properties in 49 states with a gross leasable area of approximately 35.3 million square feet and with a weighted average remaining lease term of 10.3 years. NNN is one of only three publicly traded REITs to have increased annual dividends for 33 or more consecutive years.
Earnings Per Share
As for profitability, National Retail Properties has a trailing twelve months EPS of $2.13.
PE Ratio
National Retail Properties has a trailing twelve months price to earnings ratio of 18.38. Meaning, the purchaser of the share is investing $18.38 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.46%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is a negative 2% and a negative 4%, respectively.
